Craig Slingluff

Director/Miembro de la Junta en Cancer Research Institute .

Health Services

Health Technology

Perfil

Craig Slingluff is a member of the Scientific Advisory Council at Cancer Research Institute and a member of the Scientific Advisory Board at Immatics Biotechnologies GmbH.

Cargos activos de Craig Slingluff

Empresas	Cargo	Inicio
Cancer Research Institute Cancer Research Institute Medical/Nursing ServicesHealth Services Cancer Research Institute provides cancer immunotherapy services. The private company is based in New York, NY and has subsidiaries in the United States. The company was founded in 1953. Jill O'Donnell-Tormey has been the CEO of the company since 1987.	Director/Miembro de la Junta	-
Immatics Biotechnologies GmbH Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.	Corporate Officer/Principal	-

Todos los cargos activos de Craig Slingluff

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Craig Slingluff.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	2
Cancer Research Institute Cancer Research Institute Medical/Nursing ServicesHealth Services Cancer Research Institute provides cancer immunotherapy services. The private company is based in New York, NY and has subsidiaries in the United States. The company was founded in 1953. Jill O'Donnell-Tormey has been the CEO of the company since 1987.	Health Services
Immatics Biotechnologies GmbH Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.	Health Technology